Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Dec;340(6):712-4.
doi: 10.1007/BF00717749.

Dual action of clonidine on insulin release: suppression, but stimulation when alpha 2-adrenoceptors are blocked

Affiliations

Dual action of clonidine on insulin release: suppression, but stimulation when alpha 2-adrenoceptors are blocked

A Schulz et al. Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec.

Abstract

As shown previously clonidine reduces glucose-stimulated insulin release and this effect is mediated by inhibitory postsynaptic alpha 2-adrenoceptors. The present experiments demonstrate that clonidine has the additional property to also stimulate insulin release. This became evident when the alpha 2-adrenoceptors of isolated islets were blocked by benextramine, and thus protected from being stimulated by clonidine. In the presence of benextramine, clonidine no longer reduced, but on the contrary enhanced, the release of insulin in response to glucose. In control experiments benextramine by itself failed to affect insulin release from isolated islets. These results show that the imidazoline derivative clonidine shares the property of other imidazoline compounds to enhance the insulin response to glucose. All of these agents may stimulate insulin by binding to "imidazoline-preferring" sites, that clearly differ from alpha-adrenoceptors.

PubMed Disclaimer

References

    1. Mol Pharmacol. 1987 Aug;32(1):241-8 - PubMed
    1. Diabetes. 1980 Mar;29(3):193-200 - PubMed
    1. Horm Metab Res. 1981 Nov;13(11):648-9 - PubMed
    1. Eur J Pharmacol. 1980 Aug 8;65(4):421-4 - PubMed
    1. Mol Pharmacol. 1989 Mar;35(3):324-30 - PubMed

Publication types